Skip to content
Study details
Enrolling now

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Alessa Therapeutics Inc.
NCT IDNCT06257693ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

20

Study length

about 1.2 years

Ages

21+

Sex

Male only

Locations

7 sites in IL, LA, MD +4

What this study is about

Researchers are testing whether a treatment called Enolen, which delivers enzalutamide directly into the prostate, is safe and effective for men with prostate cancer who are planning surgery. The trial will involve placing implants containing enzalutamide into the prostate of up to 20 participants. Participants will undergo MRI scans before and after implant placement, as well as follow-up visits to monitor their health and quality of life.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take enzalutamide

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

enzalutamide

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Measurement of Pharmacokinetics Profile, To assess the adverse events associated with the Enolen implant

Secondary: MRI changes